XASE: CVM
- Last Close 1.20
- Sector Healthcare
- Industry Biotechnology
- Investment Style Small Blend
- Day Range 1.15 – 1.25
- Year Range 1.08 – 3.68
- Market Cap 56.7121 Mil
- Volume / Avg 17.0 / 336,810.0
- Price / Sales —
- Price / Book 3.63
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis CVM
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile CVM
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
CEL-SCI Corp
XASE: CVM
| AIM ImmunoTech Inc
XASE: AIM
| Cardiff Oncology Inc
XNAS: CRDF
| Atossa Therapeutics Inc
XNAS: ATOS
| |
Price
| 1.20 | 0.51 | 1.61 | 0.77 |
Currency
| USD | USD | USD | USD |
Change
| −$0.08 (6.25%) | −$0.06 (11.06%) | $0.00 (0.00%) | −$0.06 (7.10%) |
Market Cap
| 56.71 Mil | 24.79 Mil | 71.93 Mil | 96.99 Mil |
Industry
| Biotechnology | Biotechnology | Biotechnology | Biotechnology |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for CEL-SCI Corp Stock
No. CVM does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
CVM’s market cap is 56.71 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
CVM’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
CVM’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare CVM’s historical performance against its industry peers and the overall market.